HRP20202014T1 - Supstituirani nukleozidi, nukleotidi i njihovi analozi za uporabu u liječenju virusne infekcije - Google Patents

Supstituirani nukleozidi, nukleotidi i njihovi analozi za uporabu u liječenju virusne infekcije Download PDF

Info

Publication number
HRP20202014T1
HRP20202014T1 HRP20202014TT HRP20202014T HRP20202014T1 HR P20202014 T1 HRP20202014 T1 HR P20202014T1 HR P20202014T T HRP20202014T T HR P20202014TT HR P20202014 T HRP20202014 T HR P20202014T HR P20202014 T1 HRP20202014 T1 HR P20202014T1
Authority
HR
Croatia
Prior art keywords
linked
image
optionally substituted
compound
group
Prior art date
Application number
HRP20202014TT
Other languages
English (en)
Inventor
Lawrence M. Blatt
Leonid Beigelman
Julian Alexander Symons
David Bernard Smith
Original Assignee
Janssen Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biopharma, Inc. filed Critical Janssen Biopharma, Inc.
Publication of HRP20202014T1 publication Critical patent/HRP20202014T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (24)

1. Spoj formule (I), ili njegova farmaceutski prihvatljiva sol, za uporabu u ublažavanju ili liječenju virusne infekcije, pri čemu spoj formule (I) ima strukturu: [image] naznačen time što: B1A je [image] ili [image] pri čemu RG2 je nesupstituirani C1-6 alkil; R3A je odabran iz skupine koju čine halo, OH, -OC(=O)R"A i po izboru supstituirana O-vezana α-aminokiselina; R4A je odabran iz skupine koju čine OH ili halo; Ra1 i Ra2 su neovisno vodik ili deuterij; RA je vodik ili deuterij; R1A je odabran iz skupine koju čine vodik, [image] i [image] R2A je halo ili -(CH2)1-6 halogen; R5A je odabran iz skupine koju čine nesupstituirani C1-6 alkil, nesupstituirani C2-6 alkenil i nesupstituirani C2-6 alkinil; R6A i R7A su neovisno odabrani iz skupine koju čine odsutan, vodik [image] ili R6A je [image] i R7A je odsutan ili vodik; R8A je odsutan, vodik, po izboru supstituiran fenil ili po izboru supstituiran naftil; R9A je po izboru supstituirana N-vezana α-aminokiselina odabrana iz skupine koja sadrži N-vezani alanin, N-vezani asparagin, N-vezani aspartat, N-vezani cistein, N-vezani glutamat, N-vezani glutamin, N-vezani glicin, N-vezani prolin, N-vezani serin, N-vezani tirozin, N-vezani arginin, N-vezani histidin, N-vezani izoleucin, N-vezani leucin, N-vezani lizin, N-vezani metionin, N-vezani fenilalanin, N-vezani treonin, N-vezani triptofan i N-vezani valin, ili po izboru supstituirani derivat estera N-vezane α-aminokiseline, pri čemu je po izboru supstituirani derivat estera N-vezane α- aminokiseline nesupstituirani C1-6 alkil ester, po izboru supstituiran C3-6 cikloalkil ester, po izboru supstituiran C6 aril ester, po izboru supstituiran C10 aril ester ili po izboru supstituiran benzil ester N-vezane α-aminokiseline koja se bira iz skupine koja sadrži N-vezani alanin, N-vezani asparagin, N-vezani aspartat, N-vezani cistein, N-vezani glutamat, N-vezani glutamin, N-vezani glicin, N-vezani prolin, N-vezani serin, N-vezani tirozin, N-vezani arginin, N-vezani histidin, N-vezani izoleucin, N-vezani leucin, N-vezani lizin, N-vezani metionin, N-vezani fenilalanin, N-vezani treonin, N-vezani triptofan i N-vezani valin; R10A i R11A su neovisno po izboru supstituirana N-vezana α-aminokiselina koja se bira iz skupine koja sadrži N-vezani alanin, N-vezani asparagin, N-vezani aspartat, N-vezani cistein, N-vezani glutamat, N-vezani glutamin, N-vezani glicin, N-vezani prolin, N-vezani serin, N-vezani tirozin, N-vezani arginin, N-vezani histidin, N-vezani izoleucin, N-vezani leucin, N-vezani lizin, N-vezani metionin, N-vezani fenilalanin, N-vezani treonin, N-vezani triptofan i N-vezani valin, ili po izboru supstituirani derivat estera N-vezane α-aminokiseline, pri čemu je po izboru supstituirani derivat estera N-vezane α-aminokiseline nesupstituirani C1-6 alkil ester, po izboru supstituiran C3-6 cikloalkil ester, po izboru supstituiran C6 aril ester, po izboru supstituiran C10 aril ester ili po izboru supstituiran benzil ester N-vezane α-aminokiseline koja se bira iz skupine koja sadrži N-vezani alanin, N-vezani asparagin, N-vezani aspartat, N-vezani cistein, N-vezani glutamat, N-vezani glutamin, N-vezani glicin, N-vezani prolin, N-vezani serin, N-vezani tirozin, N-vezani arginin, N-vezani histidin, N-vezani izoleucin, N-vezani leucin, N-vezani lizin, N-vezani metionin, N-vezani fenilalanin, N-vezani treonin, N-vezani triptofan i N-vezani valin; R12A i R13A su neovisno odsutni ili vodik; R14A je O-, OH ili metil; R22A i R23A su svaki vodik; R24A je odabran iz skupine koju čine vodik, nesupstituirani C1-24 alkil i nesupstituirani -O-C1-24 alkil; R"A je nesupstituirani C1-24 alkil; m je 0 ili 1; s je 0; i Z1A, Z2A, Z3A i Z4A su svaki O; pri čemu je virusna infekcija izazvana s virusom koji je odabran iz skupine koja sadrži virus Coronaviridae, virus Togaviridae, virus Hepeviridae i virus Bunyaviridae; i kada je skupina opisana kao po izboru supstituirana, ta skupina može biti nesupstituirana ili supstituirana s jednom ili više skupina neovisno odabranih iz niza koji sadrži alkil, alkenil, alkinil, cikloalkil, cikloalkenil, aril, heteroaril, heterociklil, aril(alkil), heteroaril(alkil), (heterociklil)alkil, hidroksi, alkoksi, acil, cijano, halogen, tiokarbonil, O-karbamil, N-karbamil, O-tiokarbamil, N-tiokarbamil, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-karboksi, O-karboksi, izocijanato, tiocijanato, izotiocijanato, nitro, azido, silil, sulfenil, sulfinil, sulfonil, haloalkil, haloalkoksi, trihalometansulfonil, trihalometansulfonamido, amino, mono-supstituiranu amino skupinu i di-supstituiranu amino skupinu.
2. Spoj za uporabu prema patentnom zahtjevu 1, naznačen time što je virus član obitelji virusa Coronaviridae; poželjno Coronaviridae virus je betakoronavirus; poželjno betakoronavirus je MERS-CoV; ili pri čemu je virus član obitelji virusa Togaviridae virus; poželjno Togaviridae virus je alfavirus; poželjno alfavirus je virus venecuelskog konjskog encefalitisa ili virus Chikungunya.
3. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-2, naznačen time što R2A je halo; poželjno fluor.
4. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-2, naznačen time što R2A je -(CH2)1-6 halogen; poželjno-(CH2)1-6F.
5. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-4, naznačen time što R4A je OH.
6. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-4, naznačen time što R4A je halo; poželjno F ili Cl.
7. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-6, naznačen time što R5A je nesupstituirani C2-6 alkinil, poželjno etinil.
8. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-6, naznačen time što R5A je nesupstituirani C1-6 alkil, poželjno metil.
9. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-8, naznačen time što R1A je vodik.
10. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-8, naznačen time što R1A je [image]
11. Spoj za uporabu prema patentnom zahtjevu 10, naznačen time što su R6A i R7A neovisno odsutni ili vodik; ili pri čemu R6A je [image] R7A je odsutan ili vodik i m je 0; ili naznačen time što R6A je vodik i m je 1. [image] R7A je odsutan ili
12. Spoj za uporabu prema patentnom zahtjevu 10, naznačen time što R6A i R7A su svaki [image]
13. Spoj za uporabu prema patentnom zahtjevu 10 naznačen time što R6A i R7A su svaki izopropiloksikarboniloksimetil.
14. Spoj za uporabu [image] prema bilo kojem od patentnih zahtjeva 1-8, naznačen time što R1A je R9A ili [image]
15. Spoj za uporabu prema patentnom zahtjevu 14, naznačen time što R8A je po izboru supstituiran aril; i pri čemu je R9A po izboru supstituirana N-vezana α-aminokiselina koja se bira iz skupine koja sadrži N-vezani alanin, N-vezani asparagin, N-vezani aspartat, N-vezani cistein, N-vezani glutamat, N-vezani glutamin, N-vezani glicin, N-vezani prolin, N-vezani serin, N-vezani tirozin, N-vezani arginin, N-vezani histidin, N-vezani izoleucin, N-vezani leucin, N-vezani lizin, N-vezani metionin, N-vezani fenilalanin, N-vezani treonin, N-vezani triptofan i N-vezani valin, ili po izboru supstituirani derivat estera N-vezane α-aminokiseline, pri čemu je po izboru supstituirani derivat estera N-vezane α-aminokiseline nesupstituirani C1-6 alkil ester, po izboru supstituiran C3-6 cikloalkil ester, po izboru supstituiran C6 aril ester, po izboru supstituiran C10 aril ester ili po izboru supstituiran benzil ester N-vezane α-aminokiseline koja se bira iz skupine koja sadrži N-vezani alanin, N-vezani asparagin, N-vezani aspartat, N-vezani cistein, N-vezani glutamat, N-vezani glutamin, N-vezani glicin, N-vezani prolin, N-vezani serin, N-vezani tirozin, N-vezani arginin, N-vezani histidin, N-vezani izoleucin, N-vezani leucin, N-vezani lizin, N-vezani metionin, N-vezani fenilalanin, N-vezani treonin, N-vezani triptofan i N-vezani valin; poželjno je R8A nesupstituirani fenil; i R9A je odabran iz skupine koja se sastoji od [image] [image]
16. Spoj za uporabu prema patentnom zahtjevu 14, naznačen time što su R10A i R11A neovisno po izboru supstituirana N-vezana α-aminokiselina koja se bira iz skupine koja sadrži N-vezani alanin, N-vezani asparagin, N-vezani aspartat, N-vezani cistein, N-vezani glutamat, N-vezani glutamin, N-vezani glicin, N-vezani prolin, N-vezani serin, N-vezani tirozin, N-vezani arginin, N-vezani histidin, N-vezani izoleucin, N-vezani leucin, N-vezani lizin, N-vezani metionin, N-vezani fenilalanin, N-vezani treonin, N-vezani triptofan i N-vezani valin, ili po izboru supstituirani derivat estera N-vezane α-aminokiseline, pri čemu po izboru supstituirani derivat estera N-vezane α-aminokiseline je nesupstituirani C1-6 alkil ester, po izboru supstituiran C3-6 cikloalkil ester, po izboru supstituiran C6 aril ester, po izboru supstituiran C10 aril ester ili po izboru supstituiran benzil ester N-vezane α-aminokiseline koja se bira iz skupine koja sadrži N-vezani alanin, N-vezani asparagin, N-vezani aspartat, N-vezani cistein, N-vezani glutamat, N-vezani glutamin, N-vezani glicin, N-vezani prolin, N-vezani serin, N-vezani tirozin, N-vezani arginin, N-vezani histidin, N-vezani izoleucin, N-vezani leucin, N-vezani lizin, N-vezani metionin, N-vezani fenilalanin, N-vezani treonin, N-vezani triptofan i N-vezani valin; poželjno pri čemu su R10A i R11A neovisno odabrani iz skupine koju čine [image] [image] [image]
17. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-16, naznačen time što R3A je OH.
18. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-16, naznačen time što R3A je -OC(=O)R"A ili po izboru supstituirana O-vezana α-aminokiselina.
19. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-16, naznačen time što R3A je halo; poželjno fluor ili klor.
20. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-19, naznačen time što RA je vodik.
21. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-20, naznačen time što Ra1 i Ra2 su oba vodik.
22. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-21, naznačen time što B1A je [image]
23. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-21, naznačen time što B1A je [image] pri čemu RG2 je -CH2CH3.
24. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-2, naznačen time što je spoj s Formulom (I) odabran iz skupine koju čine: [image] [image] [image] [image] i [image] ili farmaceutski prihvatljiva sol bilo kojeg od prethodno navedenih; poželjno je spoj odabran iz skupine koju čine: [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] ili farmaceutski prihvatljiva sol bilo kojeg od prethodno navedenih.
HRP20202014TT 2014-06-24 2015-06-22 Supstituirani nukleozidi, nukleotidi i njihovi analozi za uporabu u liječenju virusne infekcije HRP20202014T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462016232P 2014-06-24 2014-06-24
US201462061770P 2014-10-09 2014-10-09
PCT/US2015/037001 WO2015200219A1 (en) 2014-06-24 2015-06-22 Substituted nucleosides, nucleotides and analogs thereof
EP15812231.7A EP3160476B1 (en) 2014-06-24 2015-06-22 Substituted nucleosides, nucleotides and analogs thereof for use in the treatment of viral infection

Publications (1)

Publication Number Publication Date
HRP20202014T1 true HRP20202014T1 (hr) 2021-04-02

Family

ID=54868668

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20202014TT HRP20202014T1 (hr) 2014-06-24 2015-06-22 Supstituirani nukleozidi, nukleotidi i njihovi analozi za uporabu u liječenju virusne infekcije

Country Status (20)

Country Link
US (2) US9603864B2 (hr)
EP (2) EP3797782A1 (hr)
JP (3) JP6728075B2 (hr)
CN (2) CN106573011A (hr)
AU (2) AU2015280248B2 (hr)
CA (2) CA3207106A1 (hr)
DK (1) DK3160476T3 (hr)
EA (1) EA201692535A1 (hr)
ES (1) ES2841310T3 (hr)
HR (1) HRP20202014T1 (hr)
HU (1) HUE051986T2 (hr)
IL (1) IL249628A0 (hr)
LT (1) LT3160476T (hr)
MX (1) MX2016017383A (hr)
PH (1) PH12016502564A1 (hr)
SG (1) SG11201610599TA (hr)
SI (1) SI3160476T1 (hr)
SM (1) SMT202000716T1 (hr)
TW (1) TW201613612A (hr)
WO (1) WO2015200219A1 (hr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
US9598457B2 (en) 2012-12-21 2017-03-21 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
BR112015014457A2 (pt) * 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
CA2908313A1 (en) 2013-04-05 2014-10-09 Alios Biopharma, Inc. Hepatitis c viral infection treatment using a combination of compounds
AU2014302711A1 (en) 2013-06-26 2015-12-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MX2015017556A (es) 2013-06-26 2016-05-09 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos.
WO2015054465A1 (en) * 2013-10-11 2015-04-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HUE051986T2 (hu) 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
MA40031A (fr) 2014-06-24 2015-12-30 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
AU2015320511B2 (en) * 2014-09-26 2020-11-12 Riboscience Llc 4'-vinyl substituted nucleoside derivatives as inhibitors of Respiratory Syncytial Virus RNA replication
WO2016069489A1 (en) 2014-10-28 2016-05-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) * 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
US10208045B2 (en) 2015-03-11 2019-02-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
CN105503787A (zh) * 2015-12-31 2016-04-20 阜阳欣奕华材料科技有限公司 一种索非布韦中间体的纯化方法
US9988416B2 (en) * 2016-03-24 2018-06-05 Novartis Ag Alkynyl nucleoside analogs as inhibitors of human rhinovirus
EA201892448A1 (ru) * 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
EP3510040A4 (en) 2016-09-09 2020-06-03 Calithera Biosciences, Inc. EKTONUCLEOTIDASE INHIBITORS AND METHOD FOR USE THEREOF
EP3556764A4 (en) 2016-12-16 2021-01-06 Gifu University NUCLEOSIDE DERIVATIVE AND USE FOR IT
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
CA3059777C (en) 2017-05-01 2023-02-21 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
EP3661513A4 (en) 2017-07-31 2021-07-14 January Therapeutics, Inc. ORGANOPHOSPHATE DERIVATIVES
CA3075950A1 (en) * 2017-09-18 2019-03-21 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
JP7173467B2 (ja) 2017-10-31 2022-11-16 ヤマサ醤油株式会社 ヌクレオシド誘導体及びその利用
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
US20210038628A1 (en) * 2018-03-02 2021-02-11 January Therapeutics, Inc. Nanoparticle compositions
KR20200140274A (ko) * 2018-03-07 2020-12-15 에모리 유니버시티 4'-할로겐 함유 뉴클레오티드 및 뉴클레오시드 치료 조성물 및 이와 관련된 용도
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
CN113811360A (zh) 2019-03-06 2021-12-17 葛兰素史密斯克莱知识产权（第2 号）有限公司 用于hiv治疗的化合物
KR20240113860A (ko) * 2019-04-05 2024-07-23 가부시기가이샤 닛뽕쇼꾸바이 가교형 인공 뉴클레오시드의 제조
CN118477090A (zh) * 2019-10-08 2024-08-13 埃默里大学 含4'-卤素的核苷酸和核苷治疗组合物以及其相关用途
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN113387954B (zh) * 2020-03-11 2024-03-19 上海特化医药科技有限公司 一种瑞德西韦中间体的制备方法
KR20220153619A (ko) 2020-03-12 2022-11-18 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오사이드의 제조 방법
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CA3167268A1 (en) * 2020-03-27 2021-09-30 Ioannis PAPASOTIRIOU Nucleotide analogues for the treatment of coronaviruses
EP4130018A4 (en) * 2020-03-27 2024-04-17 Sumitomo Chemical Company, Limited METHOD FOR PRODUCING A NUCLEIC ACID OLIGOMER
CA3172483A1 (en) 2020-04-06 2021-10-14 Scott Ellis Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
AR121836A1 (es) * 2020-04-14 2022-07-13 Janssen Sciences Ireland Unlimited Co Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
PE20230618A1 (es) 2020-06-24 2023-04-14 Gilead Sciences Inc Analogos de nucleosido de 1'-ciano y usos de los mismos
IL300412A (en) 2020-08-24 2023-04-01 Gilead Sciences Inc Phospholipid compounds and their uses
IL300453A (en) 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
CN112279877B (zh) * 2020-12-15 2021-08-06 南京颐媛生物医学研究院有限公司 一种核苷磷酸酯及其合成方法
CN113214320A (zh) * 2021-01-23 2021-08-06 河南泰丰生物科技有限公司 一种瑞德西韦化合物的制备方法
WO2022174194A1 (en) * 2021-02-15 2022-08-18 Emory University 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
MX2023011870A (es) * 2021-04-09 2023-12-07 Univ Emory Análogos de nucleósidos y de nucleótidos como agentes antivirales para coronavirus y otros virus.
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial
AU2022306289A1 (en) 2021-07-09 2024-01-18 Aligos Therapeutics, Inc. Anti-viral compounds
CN113735929A (zh) * 2021-07-21 2021-12-03 海化生命(厦门)科技有限公司 一种抗冠状病毒的化合物及其制备方法与应用
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CN115721661A (zh) * 2021-09-01 2023-03-03 常晓宇 嘌呤核苷类药物预防或治疗冠状病毒感染性疾病的用途
CN113461760B (zh) * 2021-09-06 2021-12-10 南京颐媛生物医学研究院有限公司 4-硫代脱氧胸苷衍生物及其抗乙肝病毒制药应用
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
WO2023069495A1 (en) * 2021-10-19 2023-04-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides with 2'-deoxy-2'-f-2'-c-methyl nucleotides
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
CN116554249B (zh) * 2022-01-28 2025-03-18 北京恩泰伟医药科技有限公司 抗病毒化合物及其用途
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
IL315480A (en) 2022-03-15 2024-11-01 Rome Therapeutics Inc Compounds and methods for treating disease
US20250282812A1 (en) * 2022-04-20 2025-09-11 Shanghai Institute Of Materia Medica , Chinese Academy Of Sciences Antiviral nucleoside analogue, and pharmaceutical composition and use thereof
US20260115216A1 (en) * 2022-08-10 2026-04-30 Kyushu University, National University Corporation Nucleic acid precursor
WO2024086592A2 (en) * 2022-10-17 2024-04-25 Emory Unversity 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CN116589510B (zh) * 2023-04-20 2025-08-26 安徽大学 一种氟代苄基核糖中间体的制备方法与应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
WO2002032920A2 (en) * 2000-10-18 2002-04-25 Pharmasset Limited Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
SK286630B6 (sk) 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
TW200500375A (en) * 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
US20040259934A1 (en) * 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
EP1656093A2 (en) * 2003-05-14 2006-05-17 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
WO2005020885A2 (en) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2006033709A2 (en) 2004-07-29 2006-03-30 Metabasis Therapeutics, Inc. Novel nucleoside derivatives
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
WO2008104893A2 (en) * 2007-02-28 2008-09-04 The Governors Of The University Of Alberta Compounds for preventing or treating viral infections and methods of use thereof
AR072906A1 (es) 2008-08-06 2010-09-29 Novartis Ag Nucleosidos modificados utiles como antivirales
JP2012521359A (ja) 2009-03-20 2012-09-13 アリオス バイオファーマ インク． 置換されたヌクレオシドアナログおよびヌクレオチドアナログ
WO2010108135A1 (en) * 2009-03-20 2010-09-23 Alios Biopharma, Inc. Protected nucleotide analogs
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
WO2012040126A1 (en) * 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
CN102558261A (zh) * 2010-12-17 2012-07-11 中国科学院大连化学物理研究所 一种核苷酸类似物及其合成和应用
CA2819041A1 (en) 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
CA2836579A1 (en) * 2011-05-19 2012-11-22 Rfs Pharma, Llc Purine monophosphate prodrugs for treatment of viral infections
AU2012357940B2 (en) 2011-12-20 2017-02-16 Riboscience Llc 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
CA2860234A1 (en) * 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
WO2013142159A1 (en) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US8846896B2 (en) 2012-03-21 2014-09-30 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
GEP201706721B (en) 2012-03-21 2017-08-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
FR3000193B1 (fr) 2012-12-20 2015-01-16 Msc & Sgcc Procede et dispositif de mesure de la verticalite sur un recipient
US9598457B2 (en) 2012-12-21 2017-03-21 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
BR112015014457A2 (pt) 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
WO2014164533A1 (en) 2013-03-11 2014-10-09 Vertex Pharmaceuticals Incorporated Methods of stereoselective synthesis of substituted nucleoside analogs
CA2908313A1 (en) 2013-04-05 2014-10-09 Alios Biopharma, Inc. Hepatitis c viral infection treatment using a combination of compounds
US9447132B2 (en) * 2013-04-12 2016-09-20 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
AU2014302711A1 (en) 2013-06-26 2015-12-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MX2015017556A (es) 2013-06-26 2016-05-09 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos.
LT3043803T (lt) 2013-09-11 2022-08-10 Emory University Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas
WO2015054465A1 (en) 2013-10-11 2015-04-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MA40031A (fr) 2014-06-24 2015-12-30 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
AU2015280245A1 (en) 2014-06-24 2017-01-05 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
HUE051986T2 (hu) 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
CA2955604A1 (en) 2014-07-22 2016-01-28 Alios Biopharma, Inc. Methods for treating paramyxoviruses
PE20170673A1 (es) 2014-08-05 2017-05-22 Alios Biopharma Inc Terapia de combinacion para tratar una paramixovirus
WO2016069489A1 (en) 2014-10-28 2016-05-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
TW201811339A (zh) 2016-08-12 2018-04-01 美商艾洛斯生物製藥公司 經取代之核苷、核苷酸及其類似物
US20180117042A1 (en) 2016-10-27 2018-05-03 Alios Biopharma, Inc. Methods for treating respiratory syncytial virus infection

Also Published As

Publication number Publication date
PH12016502564A1 (en) 2017-04-17
CA2952966C (en) 2024-10-29
CN106573011A (zh) 2017-04-19
ES2841310T3 (es) 2021-07-08
JP7449978B2 (ja) 2024-03-14
SMT202000716T1 (it) 2021-01-05
US20170143749A1 (en) 2017-05-25
AU2015280248B2 (en) 2021-04-08
EP3160476A4 (en) 2018-01-10
SI3160476T1 (sl) 2021-05-31
HUE051986T2 (hu) 2021-04-28
EP3797782A1 (en) 2021-03-31
CA3207106A1 (en) 2015-12-30
EP3160476B1 (en) 2020-09-30
AU2015280248A1 (en) 2017-01-12
DK3160476T3 (da) 2020-12-21
IL249628A0 (en) 2017-02-28
SG11201610599TA (en) 2017-01-27
JP2017519784A (ja) 2017-07-20
WO2015200219A1 (en) 2015-12-30
CA2952966A1 (en) 2015-12-30
US10307439B2 (en) 2019-06-04
CN106573011A8 (zh) 2017-07-11
US20150366888A1 (en) 2015-12-24
EP3160476A1 (en) 2017-05-03
AU2021204791B2 (en) 2023-12-07
US9603864B2 (en) 2017-03-28
AU2021204791A1 (en) 2021-08-05
JP2022116170A (ja) 2022-08-09
EA201692535A1 (ru) 2017-05-31
MX2016017383A (es) 2017-08-02
TW201613612A (en) 2016-04-16
JP2020172511A (ja) 2020-10-22
CN117379452A (zh) 2024-01-12
LT3160476T (lt) 2021-04-12
JP6728075B2 (ja) 2020-07-22
JP7080928B2 (ja) 2022-06-06

Similar Documents

Publication Publication Date Title
HRP20202014T1 (hr) Supstituirani nukleozidi, nukleotidi i njihovi analozi za uporabu u liječenju virusne infekcije
HRP20211224T1 (hr) Derivati pirimidina za liječenje virusnih infekcija
JP2017519784A5 (hr)
EA201992082A1 (ru) Ингибитор поверхностного антигена вируса гепатита b
AR089408A1 (es) Nucleosidos sustituidos, nucleotidos y analogos de los mismos para ser empleados en el tratamiento de enfermedades virales
JP2017503777A5 (hr)
IL292262A (en) Oral dosage formulation of {[ 5-(3-(chlorophenyl)- 3-hydroxypyridine-2-carbonyl] amino} acetic acid
JP2016530315A5 (hr)
BR112014000834A2 (pt) compostos modificadores de sabor
NZ603232A (en) Nucleoside phosphoramidates
ES2396595T3 (es) Composición farmacéutica que contiene un derivado de pirazina y método de utilización de un derivado de pirazina en combinación
EA201491179A1 (ru) 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
EA201491180A1 (ru) 4'-азидо,3'-фторзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гепатита с
UA115043C2 (uk) Амідні похідні n-карбамідзаміщених амінокислот як модулятори формілпептидного рецептора 1 (fprl-1)
EA201100482A1 (ru) Кристаллические формы 2-тиазолил-4-хинолинилоксипроизводного, активного ингибитора hcv
EA201490610A1 (ru) Соединения и способы усиления врожденных иммунных ответов
UA108221C2 (uk) Похідні тіофен-2-карбонової кислоти як інгібітори вірусів flaviviridae
SI2707385T1 (en) Pregnant RSV F antigens
PE20160658A1 (es) Nucleosidos sustituidos, nucleotidos y analogos de los mismos
EA201690623A1 (ru) Простациклиновые соединения, композиции и способы их использования
BR112012017382A2 (pt) compostos inibidores de viroses flaviviridae, uso dos mesmos e composição farmacêutica
DK3986561T3 (da) Pyrido[2,3-D]pyrimidin-derivater som inhibitorer af replikationen af human immundefektvirus
HRP20161680T1 (hr) Farmaceutski pripravak koji sadrži ne-nukleozidni inhibitor reverzne transkriptaze
EA201691554A1 (ru) 4'-дифторметилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гриппа
HRP20211278T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa